2024
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bagatell R, Park J, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai A, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 413-433. PMID: 39151455, DOI: 10.6004/jnccn.2024.0040.Peer-Reviewed Original ResearchConceptsNCCN GuidelinesNCCN Clinical Practice GuidelinesClinically heterogeneous diseaseExtracranial solid tumorTreatment of neuroblastomaClinical practice guidelinesNeuroblastoma panelRadiation oncologistsNCCN Member InstitutionsSolid tumorsHeterogeneous diseaseConsensus recommendationsPediatric oncologistsNeuroblastomaNCCNGroup of representativesRisk classificationEvidence-basedMultidisciplinary groupPractice guidelinesOncologistsMember institutionsGuidelinesTreatmentTumorManagement of recurrent and persistent malignant ovarian germ cell tumors: a narrative review
Nasioudis D, Pashankar F. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review. International Journal Of Gynecological Cancer 2024, ijgc-2023-005052. PMID: 38991656, DOI: 10.1136/ijgc-2023-005052.Peer-Reviewed Original ResearchMalignant ovarian germ cell tumorsOvarian germ cell tumorsGerm cell tumorsCell tumorsHigh-dose chemotherapy protocolsPlatinum-resistant diseasePlatinum-sensitive diseaseSecondary cytoreductive surgeryPlatinum-based chemotherapyStandard dose chemotherapyCytoreductive surgeryDose chemotherapyTumor relapseOptimal resectionChemotherapy protocolsGenomic alterationsSpecialized centersTumorTherapeutic approachesSensitive diseasePatientsChemotherapyNarrative reviewOptimal timingDiseaseConsensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective
Pashankar F, Murray M, Gell J, MacDonald N, Shamash J, Billmire D, Klosterkemper L, Olson T, Hirsch M, Lockley M, Stoneham S, Frazier A. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. EClinicalMedicine 2024, 69: 102453. PMID: 38544795, PMCID: PMC10965411, DOI: 10.1016/j.eclinm.2024.102453.Peer-Reviewed Original ResearchOvarian immature teratomaImmature teratomaElevated serum alpha-fetoproteinSurgery-only approachSerum alpha-fetoproteinOvarian ITStage IAAdjuvant chemotherapyRare neoplasmsOvarian cancerAdult patientsAlpha-fetoproteinLack of published dataPathologic interpretationPatient managementLow-gradeGrade 1Multiple subspecialtiesPatientsTeratomaYoung femalesAdult practiceNational advisory panelPaediatric teamGCTP3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Mak B, Tran B, Pashankar F, Mazhar D, Huddart R, Wheater M, Walpole E, Feldman D, Dunwoodie E, Lawrence N, Birtle A, Wyld D, Stevanovic A, Balagtas J, Stockler M, Davis I. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2024, 42: tps524-tps524. DOI: 10.1200/jco.2024.42.4_suppl.tps524.Peer-Reviewed Original ResearchMetastatic germ cell tumorsGerm cell tumorsPhase 3 trialTwo-sided type I error rateRandomized trials of chemotherapyRandomized phase 3 trialResponse rateProgression free survivalFirst-line chemotherapyStandard chemotherapy regimensFavorable response rateImprove cure ratesTrials of chemotherapyBaseline blood samplesPost-chemotherapy treatmentStage 1BEP chemotherapyStandard BEPTranslational substudyFree survivalChemotherapy regimensOpen-labelStage 2Primary endpointCell tumorsNormal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain
Prior D, Sowa A, Pashankar F. Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain. Journal Of Pediatric Hematology/Oncology 2024, 46: e195-e198. PMID: 38277626, DOI: 10.1097/mph.0000000000002820.Peer-Reviewed Original ResearchConceptsDiamond-Blackfan anemiaDiamond-BlackfanDiagnosis of Diamond-Blackfan anemiaInherited bone marrow failure syndromeBone marrow failure syndromesMarrow failure syndromesDiagnostically challenging casesFailure syndromeAtypical manifestationsSpontaneous remissionRare caseErythroid precursorsChallenging casesGenetic etiologyPhenotypic manifestationsAnemiaPatientsRemissionRelapseHypoplasiaSyndromeEtiologyDiagnosis
2023
Standardized Clinical Pathways Improve Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department
Forward J, Thomas D, O'Malley S, Berkwitt A, Calhoun C, Krishnamurti L, Pashankar F. Standardized Clinical Pathways Improve Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department. Blood 2023, 142: 2315. DOI: 10.1182/blood-2023-181285.Peer-Reviewed Original ResearchVaso-occlusive episodesSickle cell diseasePediatric emergency departmentMinutes of arrivalPain managementEmergency departmentClinical pathwayIntranasal fentanylYears post implementationHydromorphone PCAPain medicationPediatric patientsJune 30 thPain medication administrationVaso-occlusive painPercent of patientsPercentage of patientsQuality improvement projectOutcome one yearElectronic medical recordsPost implementationHealth care systemFirst analgesicED visitsED encountersLoss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whitesP3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Zebic D, Stockler M, Martin A, Pashankar F, Tran B, Mazhar D, Huddart R, Wheater M, Walpole E, Dunwoodie E, Feldman D, Birtle A, Stevanovic A, Wyld D, Hanning F, Grimison P, Group A. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2023, 41: tps431-tps431. DOI: 10.1200/jco.2023.41.6_suppl.tps431.Peer-Reviewed Original ResearchPoor-risk metastatic germ cell tumoursMetastatic germ cell tumorsGerm cell tumorsPhase 3 trialStandard BEPComplete responseStage ITwo-sided type IRandomized phase 3 trialCisplatin 20mg/Standard BEP chemotherapyBaseline blood samplesProgression-free survivalTrial of chemotherapyImproved cure ratesD1-5Post-chemotherapy treatmentTranslational substudyBEP chemotherapyLine chemotherapyOpen labelPrimary endpointStandard regimensFree survivalCR rate
2022
Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease
Gillard A, Gagnon R, Pashankar F, Balsamo L, Grafft N, Miranda J, Boruchov D, Neri C, Sprinz P, Longyear C. Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease. Clinical Child Psychology And Psychiatry 2022, 28: 1012-1023. PMID: 36503316, DOI: 10.1177/13591045221145425.Peer-Reviewed Original ResearchMetastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide
Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide. Pediatric Blood & Cancer 2022, 70: e30020. PMID: 36151992, DOI: 10.1002/pbc.30020.Peer-Reviewed Original ResearchAddressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference
Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L, Hirsch MS. Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. European Journal Of Cancer 2022, 173: 59-70. PMID: 35863107, DOI: 10.1016/j.ejca.2022.06.006.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaImmature teratomaGerm cell tumor elementsSerum alpha-fetoproteinGerm cell tumorsYolk sac tumorSerum tumor biomarkersForm of sarcomaTherapeutic dilemmaSac tumorRare subtypeSomatic malignancyCell tumorsNeuroectodermal elementsNeuroectodermal componentConsensus conferenceAlpha-fetoproteinTumor elementsManagement dilemmaAdult womenPractice differencesTumor biomarkersTeratomaTumorsClinicopathologic conferenceUtility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group
Dicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group. Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.Peer-Reviewed Original ResearchConceptsIntra-operative frozen sectionOvarian germ cell tumorsGerm cell tumorsMalignant ovarian germ cell tumorsIntra-operative frozen section diagnosisFrozen section diagnosisCentral pathology reviewCell tumorsSurgical stagingAdolescent patientsFinal diagnosisFinal paraffin section diagnosisSection diagnosisFrozen sectionsParaffin section diagnosisOncology GroupPathology reviewCentral reviewOvarian germ cell malignanciesNonseminomatous germ cell tumorsGerm cell tumor componentsConfirmation of malignancyGerm cell malignanciesRecords of patientsChildren's Oncology GroupThe United States
Pashankar F, Rodriguez-Galindo C. The United States. EJC Paediatric Oncology 2022, 55-58. DOI: 10.1007/978-3-030-92071-5_7.Peer-Reviewed Original Research
2021
Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt
Youssry I, ElGhamrawy M, Seif H, Balsamo L, Pashankar F, Mahrous M, Salama N. Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt. International Journal Of Hematology 2021, 115: 399-405. PMID: 34792734, DOI: 10.1007/s12185-021-03260-1.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh lactate dehydrogenaseCell diseaseCognitive impairmentRisk factorsLactate dehydrogenaseCairo University Children's HospitalOlder ageSickle cell disease patientsUniversity Children's HospitalPossible risk factorsMagnetic resonance angiographyMagnetic resonance imagingHydroxyurea therapyTranscranial DopplerChildren's HospitalDisease patientsUnivariate analysisEarly initiationPatientsResonance angiographyImpaired cognitionResonance imagingIntelligence quotient (IQ) testDiseaseRe: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’
Lockley M, Stoneham S, Shamash J, Pashankar F, Frazier L. Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’. European Journal Of Cancer 2021, 152: 255-256. PMID: 34099362, DOI: 10.1016/j.ejca.2021.05.001.Peer-Reviewed Original ResearchTreatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol
Rodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB, Malkin D, Wasserman JD, de Oliveira Filho AG, LaQuaglia MP, Ward DA, Zambetti G, Mastellaro MJ, Pappo AS, Ribeiro RC. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal Of Clinical Oncology 2021, 39: 2463-2473. PMID: 33822640, PMCID: PMC8462560, DOI: 10.1200/jco.20.02871.Peer-Reviewed Original ResearchConceptsRetroperitoneal lymph node dissectionLymph node dissectionOutcomes of patientsAdrenocortical carcinomaNode dissectionStage IOncology GroupStage IV adrenocortical carcinomaStage-III adrenocortical carcinomaPediatric-specific studiesStage II diseaseEvent-free survivalStage II patientsThird of patientsOverall survival estimatesChildren's Oncology GroupHigh-risk groupCombination of mitotaneAggressive pediatric malignancyPediatric adrenocortical carcinomaAdvanced diseaseII patientsMultivariable analysisPoor outcomeExcellent outcomesBone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia
Gorfinkel L, Demsky C, Pashankar F, Kupfer G, Shah NC. Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia. Pediatric Transplantation 2021, 25: e14009. PMID: 33755277, DOI: 10.1111/petr.14009.Peer-Reviewed Original ResearchConceptsUnrelated donor transplantsDonor transplantsBM graftsVivo T-cell depletionReduced intensity conditioning regimenStem cell transplant programInclusion of alemtuzumabNon-TBI conditioningPost-transplant complicationsSuccess of HSCTDevelopment of GVHDT-cell depletionIntensity conditioning regimenBone marrow transplantFull immune reconstitutionChronic GVHDCyclophosphamide conditioningGVHD prophylaxisMSD transplantsImmune reconstitutionConditioning regimenLate complicationsConditioning regimensSecondary neoplasmsSecondary malignanciesRacial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors
Puthenpura V, Canavan ME, Poynter JN, Roth M, Pashankar FD, Jones BA, Marks AM. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. Pediatric Blood & Cancer 2021, 68: e28970. PMID: 33704901, PMCID: PMC8221084, DOI: 10.1002/pbc.28970.Peer-Reviewed Original ResearchConceptsHazard of deathCentral nervous system tumorsNervous system tumorsRace/ethnicitySocioeconomic statusSystem tumorsMultivariate Cox proportional hazards modelNon-Hispanic black patientsNon-Hispanic white patientsPrimary central nervous system tumorsCox proportional hazards modelEnd Results (SEER) databaseRetrospective cohort studyPrimary CNS tumorsYoung adult patientsNeuro-oncology patientsProportional hazards modelLowest SES tertileLow socioeconomic statusNHB patientsAYA patientsHazard ratioNHW patientsAdult patientsCohort studyP3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Subramaniam S, Toner G, Stockler M, Martin A, Pashankar F, Tran B, Jeffery M, Mazhar D, Huddart R, Walpole E, Stevanovic A, Wyld D, Hanning F, Wheater M, Balagtas J, Troon S, Birtle A, White J, Grimison P. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2021, 39: tps390-tps390. DOI: 10.1200/jco.2021.39.6_suppl.tps390.Peer-Reviewed Original ResearchMetastatic germ cell tumorsPoor-risk metastatic germ cell tumoursGerm cell tumorsStandard BEPComplete responseStage IInternational randomized phase III trialRandomized phase III trialStandard first-line chemotherapyCisplatin 20mg/Standard BEP chemotherapyBaseline blood samplesFirst-line chemotherapyPhase III trialsProgression-free survivalTrial of chemotherapyD1-5Post-chemotherapy treatmentClinical trial informationTranslational substudyBEP chemotherapyOpen labelPrimary endpointStandard regimensFree survivalPulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance
Ullrich SJ, Worhunsky D, Rodwin R, Pashankar F, Christison-Lagay E, Ozgediz D. Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance. Journal Of Pediatric Hematology/Oncology 2021, 43: e184-e186. PMID: 31815890, DOI: 10.1097/mph.0000000000001693.Peer-Reviewed Case Reports and Technical Notes